Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.

× No keyword cloud information.

18 in total

1. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.

Authors: J A Vrana; R H Decker; C R Johnson; Z Wang; W D Jarvis; V M Richon; M Ehinger; P B Fisher; S Grant
Journal: Oncogene Date: 1999-11-25 Impact factor: 9.867

Review 2. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.

Authors: Francesca Merchionne; Pasquale Procaccio; Franco Dammacco
Journal: Crit Rev Oncol Hematol Date: 2010-10-29 Impact factor: 6.312

Review 3. Anticancer activities of histone deacetylase inhibitors.

Authors: Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal: Nat Rev Drug Discov Date: 2006-09 Impact factor: 84.694

4. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

Authors: Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Journal: Mol Cell Biol Date: 2005-07 Impact factor: 4.272

5. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors: Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal: Blood Date: 2006-05-25 Impact factor: 22.113

6. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Authors: Teru Hideshima; James E Bradner; Jason Wong; Dharminder Chauhan; Paul Richardson; Stuart L Schreiber; Kenneth C Anderson
Journal: Proc Natl Acad Sci U S A Date: 2005-06-03 Impact factor: 11.205

7. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

Authors: A A Ruefli; M J Ausserlechner; D Bernhard; V R Sutton; K M Tainton; R Kofler; M J Smyth; R W Johnstone
Journal: Proc Natl Acad Sci U S A Date: 2001-09-04 Impact factor: 11.205

8. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

Authors: Chunrong Yu; Mohamed Rahmani; Daniel Conrad; Mark Subler; Paul Dent; Steven Grant
Journal: Blood Date: 2003-07-31 Impact factor: 22.113

9. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

Authors: Laurence Catley; Ellen Weisberg; Yu-Tzu Tai; Peter Atadja; Stacy Remiszewski; Teru Hideshima; Nicholas Mitsiades; Reshma Shringarpure; Richard LeBlanc; Dharminder Chauhan; Nikhil C Munshi; Robert Schlossman; Paul Richardson; James Griffin; Kenneth C Anderson
Journal: Blood Date: 2003-06-19 Impact factor: 22.113

10. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.

Authors: Z Xia; M Dickens; J Raingeaud; R J Davis; M E Greenberg
Journal: Science Date: 1995-11-24 Impact factor: 47.728

1 in total

Review 1. Novel treatment options for Waldenström macroglobulinemia.

Authors: Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal: Clin Lymphoma Myeloma Leuk Date: 2013-09

1 in total